PEN Overview

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Wall Street analysts forecast PEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is344.64 USD with a low forecast of 266.00 USD and a high forecast of 388.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Penumbra Inc revenue for the last quarter amounts to 385.38M USD, increased 22.14

Penumbra Inc. EPS for the last quarter amounts to 1.20 USD, increased 46.34

Penumbra Inc (PEN) has 4700 emplpoyees as of March 10 2026.

Today PEN has the market capitalization of 13.33B USD.